Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Shukui Qin et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingJørn Herrstedt, Florian Scotté, Rebecca Clark-Snow et al.|ESMO Open|2024Cited by 141